{"nctId":"NCT02715726","briefTitle":"Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia","startDateStruct":{"date":"2016-07-27","type":"ACTUAL"},"conditions":["Hypercholesterolemia"],"count":615,"armGroups":[{"label":"Ezetimibe 10 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Placebo for alirocumab","Drug: ezetimibe","Drug: atorvastatin","Drug: rosuvastatin","Drug: simvastatin"]},{"label":"Alirocumab 75 mg Q2W/up to 150 mg Q2W","type":"EXPERIMENTAL","interventionNames":["Drug: Alirocumab","Drug: placebo for ezetimibe","Drug: atorvastatin","Drug: rosuvastatin","Drug: simvastatin"]}],"interventions":[{"name":"Alirocumab","otherNames":["SAR236553 (REGN727)"]},{"name":"Placebo for alirocumab","otherNames":[]},{"name":"ezetimibe","otherNames":[]},{"name":"placebo for ezetimibe","otherNames":[]},{"name":"atorvastatin","otherNames":[]},{"name":"rosuvastatin","otherNames":[]},{"name":"simvastatin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\nParticipants with hypercholesterolemia and established coronary heart disease (CHD) or CHD risk equivalents who are not adequately controlled with a maximally tolerated daily dose of statin at a stable dose for at least 4 weeks prior to the screening visit (Week -3).\n\nExclusion criteria:\n\n* Participants without established CHD or CHD risk equivalents.\n* LDL-C \\<70 mg/dL (\\<1.81 mmol/L) at the screening visit (Week -3) in participants with history of documented CV disease.\n* LDL-C \\<100 mg/dL (\\<2.59 mmol/L) at the screening visit (Week -3) in participants without history of documented CV disease.\n* Change in statin dose or dose regimen from screening to randomization.\n* Currently taking a statin other than atorvastatin, rosuvastatin, or simvastatin.\n* Atorvastatin, rosuvastatin, or simvastatin was not taken daily or not taken at a registered dose.\n* Daily doses above atorvastatin 80 mg, rosuvastatin 40 mg, or simvastatin 40 mg.\n* Use of cholesterol absorption inhibitor (ie, ezetimibe), omega-3 fatty acid (at doses â‰¥1000 mg daily), nicotinic acid, fibrates, bile acid-binding sequestrant, or red yeast rice products in the past 4 weeks prior to screening visit (Week -3).\n* Fasting serum triglycerides \\>400 mg/dL (\\>4.52 mmol/L) at the screening period.\n\nThe above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 24: Intent-to-treat (ITT) Analysis","description":"Adjusted least square (LS) means and standard errors at Week 24 were obtained from mixed models analysis with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.3","spread":"2.0"},{"groupId":"OG001","value":"-56.0","spread":"1.5"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 24: On-Treatment Analysis","description":"Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first) (on-treatment analysis).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.3","spread":"2.0"},{"groupId":"OG001","value":"-58.7","spread":"1.4"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 12: ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.2","spread":"1.9"},{"groupId":"OG001","value":"-57.1","spread":"1.4"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 12: On-Treatment Analysis","description":"Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first) (on-treatment analysis).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.7","spread":"1.9"},{"groupId":"OG001","value":"-58.1","spread":"1.4"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24: ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.2","spread":"1.4"},{"groupId":"OG001","value":"-43.5","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein B at Week 24: On-Treatment Analysis","description":"Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first) (on-treatment analysis).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.4","spread":"1.4"},{"groupId":"OG001","value":"-45.2","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24: ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.4","spread":"1.7"},{"groupId":"OG001","value":"-47.0","spread":"1.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol at Week 24: On-Treatment Analysis","description":"Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first) (on-treatment analysis).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.4","spread":"1.7"},{"groupId":"OG001","value":"-49.1","spread":"1.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24: ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline data from Week 4 up to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.8","spread":"1.2"},{"groupId":"OG001","value":"-33.9","spread":"0.9"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein B at Week 12: ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.5","spread":"1.4"},{"groupId":"OG001","value":"-43.0","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol at Week 12: ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.7","spread":"1.6"},{"groupId":"OG001","value":"-47.4","spread":"1.1"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Cholesterol at Week 12: ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.9","spread":"1.2"},{"groupId":"OG001","value":"-34.2","spread":"0.8"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reaching Calculated Low Density Lipoprotein Cholesterol <70 mg/dL (1.81 mmol/L) at Week 24: ITT Analysis","description":"Adjusted percentages at Week 24 were obtained from multiple imputation approach for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in the imputation model.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.5","spread":null},{"groupId":"OG001","value":"85.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reaching Calculated Low Density Lipoprotein Cholesterol <70 mg/dL (1.81 mmol/L) at Week 24: On-Treatment Analysis","description":"Adjusted percentages at Week 24 were obtained from multiple imputation approach including all available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first) (on-treatment analysis).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.1","spread":null},{"groupId":"OG001","value":"87.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Week 24: ITT Analysis","description":"Adjusted means and standard errors at Week 24 were obtained from multiple imputation approach followed by robust regression model for handling missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in the imputation model.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.956","spread":"2.095"},{"groupId":"OG001","value":"-30.317","spread":"1.461"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 24: ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":"1.3"},{"groupId":"OG001","value":"8.3","spread":"0.9"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Triglycerides (TG) at Week 24: ITT Analysis","description":"Adjusted means and standard errors at Week 24 were obtained by using multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.409","spread":"1.904"},{"groupId":"OG001","value":"-14.462","spread":"1.341"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24: ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.8"},{"groupId":"OG001","value":"3.2","spread":"0.6"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lipoprotein (a) at Week 12: ITT Analysis","description":"Adjusted means and standard errors at Week 12 were obtained from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.313","spread":"2.056"},{"groupId":"OG001","value":"-30.064","spread":"1.449"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 12: ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":"1.2"},{"groupId":"OG001","value":"7.3","spread":"0.9"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Triglycerides at Week 12: ITT Analysis","description":"Adjusted means and standard errors at Week 12 were obtained by using multiple imputation approach followed by a robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.585","spread":"1.929"},{"groupId":"OG001","value":"-9.965","spread":"1.379"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein A-1 at Week 12 : ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"0.8"},{"groupId":"OG001","value":"3.7","spread":"0.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":23,"n":206},"commonTop":["Upper Respiratory Tract Infection","Accidental Overdose"]}}}